Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (PD-1) pathway
AssigneesEmory University, Dana-Farber Cancer Institute, Inc., The Brigham and Women's Hospital, Inc., President and Fellows of Harvard College
InventorsGordon Freeman, Arlene Sharpe, David M. Dorfman, Rafi Ahmed, Daniel Barber, E. John Wherry
Life of this patent
Estimating the term…
Abstract
The present invention provides methods and compositions for the treatment, prevention, or reduction of persistent infections, such as chronic infections, latent infections, and slow infections and cancer. The methods and compositions of the invention are also useful for the alleviation of one or more symptoms associated with such infections and cancer.
Claims21
A method of increasing cytotoxic activity of anergic T cells in a subject having a lymphoproliferative cancer, comprising
- administering to the subject having the lymphoproliferative cancer an effective amount of an agent that reduces the activity of a Programmed Cell Death (PD)-1 polypeptide, wherein the agent is an anti-PD-1 antibody,
- thereby increasing the cytotoxic activity of anergic T cells in the subject with the lymphoproliferative cancer, wherein the lymphoproliferative cancer is a Hodgkin's lymphoma.
A method of increasing cytotoxic activity of anergic T cells in a subject having a lymphoproliferative cancer, comprising
- administering to the subject having the lymphoproliferative cancer an effective amount of (a) an agent that reduces the activity of a Programmed Cell Death (PD)-1 polypeptide, wherein the agent is an anti-PD-1 antibody or an anti-Programmed Cell Death Ligand (PD-L1) antibody, and (b) an anti-CTLA-4 antibody,
- thereby increasing the cytotoxic activity of anergic T cells in the subject with the lymphoproliferative cancer, wherein the lymphoproliferative cancer is a Hodgkin's lymphoma or angioimmunoblastic T cell lymphoma.
Dependencies are inferred from the claim text.